Ron Bentsur Nuvectis Pharma, Inc. (NVCT) insider trading activity

Ron Bentsur is Chairman & CEO of Nuvectis Pharma, Inc.. Currently has a direct ownership of 3.52 Million shares of NVCT, which is worth approximately $19.3 Million. The most recent transaction as insider was on Jan 02, 2025, when has been sold 250,000 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 3.52M

8.46% 3M change

8.75% 12M change

Total Value Held $19.3 Million

RON BENTSUR Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jan 02 2025	BUY Grant, award, or other acquisition	-	250,000 Added 6.63%	3,520,924 Common Stock
Dec 24 2024	BUY Open market or private purchase	$20,925 $4.65 p/Share	4,500 Added 0.14%	3,270,924 Common Stock
Nov 15 2024	BUY Open market or private purchase	$98,400 $4.92 p/Share	20,000 Added 0.61%	3,266,424 Common Stock
May 14 2024	BUY Open market or private purchase	$13,075 $6.74 p/Share	1,940 Added 0.06%	3,246,424 Common Stock
May 10 2024	BUY Open market or private purchase	$12,800 $6.4 p/Share	2,000 Added 0.06%	3,244,484 Common Stock
Mar 18 2024	BUY Open market or private purchase	$51,449 $10.29 p/Share	5,000 Added 0.15%	3,242,484 Common Stock
Oct 10 2023	BUY Open market or private purchase	$7,091 $11.08 p/Share	640 Added 0.02%	3,237,484 Common Stock
Oct 09 2023	BUY Open market or private purchase	$9,287 $11.19 p/Share	830 Added 0.03%	3,236,844 Common Stock
Oct 06 2023	BUY Open market or private purchase	$2,817 $11.27 p/Share	250 Added 0.01%	3,236,014 Common Stock
Oct 05 2023	BUY Open market or private purchase	$15,526 $11.09 p/Share	1,400 Added 0.04%	3,235,764 Common Stock
Oct 04 2023	BUY Open market or private purchase	$19,929 $10.95 p/Share	1,820 Added 0.06%	3,234,364 Common Stock
Aug 16 2023	BUY Open market or private purchase	$1,742 $15.15 p/Share	115 Added 0.0%	3,232,544 Common Stock
Aug 15 2023	BUY Open market or private purchase	$3,369 $14.34 p/Share	235 Added 0.01%	3,232,429 Common Stock
Aug 11 2023	BUY Open market or private purchase	$2,638 $14.66 p/Share	180 Added 0.01%	3,232,194 Common Stock
Aug 08 2023	BUY Open market or private purchase	$1,779 $14.83 p/Share	120 Added 0.0%	3,232,014 Common Stock
Jul 21 2023	BUY Open market or private purchase	$3,341 $14.85 p/Share	225 Added 0.01%	3,231,894 Common Stock
Jul 20 2023	BUY Open market or private purchase	$1,656 $15.06 p/Share	110 Added 0.0%	3,231,669 Common Stock
Jul 19 2023	BUY Open market or private purchase	$2,866 $14.33 p/Share	200 Added 0.01%	3,231,559 Common Stock
Jul 14 2023	BUY Open market or private purchase	$2,254 $15.03 p/Share	150 Added 0.0%	3,231,359 Common Stock
Jul 07 2023	BUY Open market or private purchase	$1,780 $16.19 p/Share	110 Added 0.0%	3,231,209 Common Stock
Jul 06 2023	BUY Open market or private purchase	$4,761 $14.88 p/Share	320 Added 0.01%	3,231,099 Common Stock
Jun 26 2023	BUY Open market or private purchase	$12,375 $16.5 p/Share	750 Added 0.02%	3,230,779 Common Stock
Jun 21 2023	BUY Open market or private purchase	$8,940 $17.88 p/Share	500 Added 0.02%	3,230,029 Common Stock
Jun 08 2023	BUY Open market or private purchase	$2,103 $17.53 p/Share	120 Added 0.0%	3,229,529 Common Stock
Jun 07 2023	BUY Open market or private purchase	$4,004 $17.41 p/Share	230 Added 0.01%	3,229,409 Common Stock

Also insider at

XAIR

Beyond Air, Inc. Healthcare

Director

Ron Bentsur

Chairman & CEO

Garden City, NY

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells NVCT shares.

Notify only if

Value

Insider Trading

Get notified when an Nuvectis Pharma, Inc. insider buys or sells NVCT shares.

Notify only if

Operation

Value

Type

News

Receive news related to Nuvectis Pharma, Inc.

Track Activities on NVCT

Account